Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 49-60 of 77 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 49-60 of 77 studies
-
Restore CFTR ProteinCompleted with Results
SNO6: Phase 2 study of N91115 in adults with CF who are currently taking lumacaftor/ivacaftor , protocol number Nivalis N91115-2CF1-05This study evaluated the safety and effectiveness of the CFTR modulator drug N91115 (cavosonstat). This study was for adults with cystic fibrosis who have two copies of the F508del CFTR mutation and were also taking lumacaftor/ivacaftor (Orkambi®).
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 85%
-
Number of Visits:
10
-
Length of Participation:
16 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of Vertex 661 and ivacaftor in people with cystic fibrosis , protocol number Vertex VX-661-107This study looked at the safety and effectiveness of the drug VX-661 in combination with ivacaftor (Kalydeco®) compared to placebo. This study was for people with CF who have one copy of the F508del CFTR mutation and a second CFTR mutation that is not likely to respond to this drug therapy.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
7
-
Length of Participation:
20 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of lumacaftor and ivacaftor in children with cystic fibrosis , protocol number Vertex VX-809-109This study evaluated the safety and effectiveness of lumacaftor and ivacaftor (Orkambi®) combination therapy in children with CF.
-
Age:
6 Years to 11 Years
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
70 to 105%
-
Number of Visits:
5
-
Length of Participation:
24 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of Vertex 661 and ivacaftor in people with CF who have one copy of the F508del-CFTR mutation and a second CFTR mutation with a gating defect responsive to ivacaftor , protocol number Vertex VX-661-109This study evaluated the safety and effectiveness of the drug VX-661 in combination with ivacaftor (Kalydeco®) in people already taking ivacaftor (Kalydeco®).
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
13 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of lumacaftor and ivacaftor in with cystic fibrosis with advanced lung disease , protocol number Vertex VX-809-106This study evaluated the safety of the drugs lumacaftor and ivacaftor (Orkambi®). This study was for people with CF who have two copies of the F508del CFTR mutation and have advanced lung disease.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
Less than 40%
-
Number of Visits:
14
-
Length of Participation:
52 weeks
-
-
Restore CFTR ProteinCompleted with Results
Phase 3 study of VX-661 and ivacaftor in people with cystic fibrosis , protocol number Vertex VX-661-106This study evaluated the safety and effectiveness of the drug VX-661 in combination with ivacaftor (Kalydeco®) compared with placebo. This study was for people with CF who have two copies of the F508del CFTR mutation.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
11
-
Length of Participation:
32 weeks
-
-
Restore CFTR ProteinCompleted with Results
Study of VX-661 combined with ivacaftor in adults with cystic fibrosis , protocol number Vertex VX-661-103This study evaluated the safety and the best way to dose VX-661 in combination with ivacaftor. This study was for adults with CF who have two copies of the F508del CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
20 weeks
-
-
Restore CFTR ProteinCompleted with Results
Vertex 809/770 in People with Cystic Fibrosis and F508del-CFTR mutation , protocol number Vertex VX-809-102This study looked at the safety and effectiveness of VX 809 (lumacaftor) when taken alone and when in combination with VX770 (ivacaftor) when given to people with CF who have either one or two copies of the F508del-CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
6
-
Length of Participation:
2 months
-
-
Restore CFTR ProteinCompleted with Results
Vertex Lumacaftor (VX-809) and Ivacaftor in People with CF aged 12 years and older and have two copies of the delF508 CFTR mutation (TRANSPORT) , protocol number Vertex VX-809-104This was the second of two nearly identical Phase 3 trials looking at the safety and effectiveness of the study drug VX 809 (lumacaftor) in combination with ivacaftor (Kalydeco) in people with CF who are aged 12 years and older and have two copies of the F508del-CFTR mutation.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
11
-
Length of Participation:
28 weeks
-
-
Restore CFTR ProteinCompleted with Results
Vertex Lumacaftor (VX-809) and ivacaftor in people with CF who are aged 12 years and have two copies of the delF508 CFTR mutation (TRAFFIC) , protocol number Vertex VX-809-103This was the first of two nearly identical Phase 3 trials looking at the safety and effectiveness of the study drug VX 809 (lumacaftor) in combination with ivacaftor in people with CF who are aged 12 years and older and have two copies of the F508del-CFTR mutation.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
10
-
Length of Participation:
24 weeks
-
-
Restore CFTR ProteinCompleted with Results
Ivacaftor in People with CF age 2 to 5 years with a CFTR Gating Mutation , protocol number Vertex VX-770-108This was an open-label study designed to look at the safety and effectiveness of ivacaftor (Kalydeco®) in children with CF who had at least one copy of a CFTR gating mutation.
-
Age:
2 Years to 5 Years
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
11
-
Length of Participation:
32 weeks
-
-
Restore CFTR ProteinCompleted with Results
Ivacaftor in People with CF who have a Non G551D Gating Mutation (KONNECTION) , protocol number Vertex VX-770-111The purpose of this trial was to look at the safety and effectiveness of ivacaftor (Kalydeco) in people with cystic fibrosis (CF) who have a non-G551D cystic fibrosis transmembrane regulator (CFTR) gating mutation (any one of the following CFTR mutations: G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D).
-
Age:
6 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 105%
-
Number of Visits:
11
-
Length of Participation:
40 weeks
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More